- Home
- DVAX
as 10-28-2025 1:59am EST
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 1.2B | IPO Year: | 2004 |
| Target Price: | $26.50 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.20 - $14.63 | Next Earning Date: | 11-05-2025 |
| Revenue: | $316,268,000 | Revenue Growth: | 26.66% |
| Revenue Growth (this year): | 23.23% | Revenue Growth (next year): | 16.57% |
Stock Insider Trading Activity of Dynavax Technologies Corporation (DVAX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Myers Scott Dunseth | DVAX | N/A | Aug 22 '25 | Buy | $10.82 | 3,800 | $41,116.00 | 35,004 | |
| Deep Track Biotechnology Master Fund, Ltd. | DVAX | N/A | Aug 22 '25 | Sell | $10.59 | 970,143 | $10,273,814.37 | 15,726,349 | |
| Deep Track Biotechnology Master Fund, Ltd. | DVAX | N/A | Aug 21 '25 | Sell | $11.03 | 1,094,994 | $12,077,783.82 | 15,726,349 |
Latest Dynavax Technologies Corporation News
DVAX Breaking Stock News: Dive into DVAX Ticker-Specific Updates for Smart Investing
PR Newswire
6 days ago
Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025
PR Newswire
7 days ago
Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial
Argus Research
4 months ago
DVAX: What does Argus have to say about DVAX?
PR Newswire
5 months ago
Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting
Argus Research
5 months ago
DVAX: Rating decreased to a SELL
Business Wire
5 months ago
Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom
PR Newswire
5 months ago
Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting
PR Newswire
5 months ago
Dynavax Comments on Glass Lewis Recommendation
Compare DVAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DVAX Dynavax Technologies Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.